Skip to main content

Inhibrx Biosciences, Inc.

INBX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002007919

In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 7 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Inhibrx Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
7 filings
3 insiders, $6.35M in total
Open-market sells
2 filings
1 insider, $279.0K in total
Insiders trading
4
Net value
+$6.07M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Inhibrx Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Inhibrx Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lappe MarkChief Executive Officer170,000IndirectOct 14, 20263
Kayyem Jon FaizDirector434,360IndirectSep 23, 20264
Forsyth DouglasDirector227,064IndirectSep 18, 20262
Vuori Kristiina MDDirector20,443Sep 18, 20261
Manhard KimberlyDirector7,500IndirectSep 18, 20263
Matly DavidPresident–Apr 27, 20261
Viking Global Investors LP10% Owner102,864IndirectOct 9, 20250
Halvorsen Ole Andreas10% Owner102,864IndirectOct 9, 20250
Ott David C.10% Owner102,864IndirectOct 9, 20250
Viking Global Opportunities Portfolio GP LLC10% Owner102,864IndirectOct 9, 20250
Viking Global Opportunities GP LLC10% Owner102,864IndirectOct 9, 20250
Viking Global Opportunities Illiquid Investments Sub-Master LP10% Owner102,864IndirectOct 9, 20250
Shabet Rose Sharon10% Owner102,864IndirectOct 9, 20250
Viking Global Opportunities Parent GP LLC10% Owner102,864IndirectOct 9, 20250
Deck KellyChief Financial Officer–Apr 2, 20250
Inhibrx, Inc.10% Owner1,157,926May 31, 20240
Eckelman Brendan P.Chief Scientific Officer40,000IndirectMay 30, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 14, 2026 (view filing)6:58 PM ETOct 14Same dayLappe MarkChief Executive OfficerPPurchase+10.0K$84.56+$849.0K+6.3%170.0K after6 lots
Sep 28, 2026 (view filing)5:47 PM ETSep 25-283 daysLappe MarkChief Executive OfficerPPurchase+10.0K$99.88+$998.8K+1.4%740.5K after4 lots
Sep 23, 2026 (view filing)4:59 PM ETSep 23Same dayKayyem Jon FaizDirectorPPurchase+5.00K$100.00+$500.0K+1.2%434.4K after
Sep 17, 2026 (view filing)5:46 PM ETSep 161 dayKayyem Jon FaizDirectorPPurchase+5.00K$100.00+$500.0K+1.2%429.4K after
Sep 15, 2026 (view filing)5:52 PM ETSep 11-154 daysManhard KimberlyDirectorSSale−1.50K$109.03−$163.5K−16.7%7.50K after3 lots
Sep 10, 2026 (view filing)7:06 PM ETSep 8-92 daysManhard KimberlyDirectorSSale−1.00K$115.47−$115.5K−10.0%9.00K after2 lots
Sep 8, 2026 (view filing)5:23 PM ETSep 8Same dayKayyem Jon FaizDirectorPPurchase+5.00K$113.52+$567.6K+1.2%424.4K after
Sep 8, 2026 (view filing)4:26 PM ETSep 8Same dayForsyth DouglasDirectorPPurchase+2.50K$114.65+$286.6K+1.1%227.1K after
Sep 8, 2026 (view filing)4:04 PM ETSep 8Same dayLappe MarkChief Executive OfficerPPurchase+25.0K$105.82+$2.65M+3.5%730.5K after6 lots
Oct 9, 2025 (view filing)4:41 PM ETOct 72 daysViking Global Investors LP and 7 others10% OwnerSSale−350.0K$32.25−$11.3M−77.3%102.9K after3 lots
Nov 22, 2024 (view filing)Nov 19-203 daysLateKayyem Jon FaizDirectorPPurchase+107.2K$14.22+$1.52MNew position69.8K after4 lots
Oct 7, 2024 (view filing)Oct 34 daysVuori Kristiina MDDirectorPPurchase+6.67K$15.00+$100.0K+48.4%20.4K after
Sep 16, 2024 (view filing)Sep 12-164 daysLappe MarkChief Executive OfficerPPurchase+40.0K$15.73+$629.1K+6.0%705.5K after2 lots
Sep 12, 2024 (view filing)Sep 10-112 daysVuori Kristiina MDDirectorPPurchase+6.64K$15.07+$100.0K+92.9%13.8K after2 lots
Sep 10, 2024 (view filing)Sep 6-104 daysLappe MarkChief Executive OfficerPPurchase+44.0K$15.25+$671.1K+7.1%665.5K after3 lots
Sep 3, 2024 (view filing)Aug 29-Sep 35 daysLappe MarkChief Executive OfficerPPurchase+40.0K$14.92+$596.8K+32.0%165.0K after4 lots
Sep 3, 2024 (view filing)Aug 295 daysVuori Kristiina MDDirectorPPurchase+7.14K$14.00+$100.0KNew position7.14K after
Aug 30, 2024 (view filing)Aug 282 daysManhard KimberlyDirectorPPurchase+10.0K$13.98+$139.8KNew position10.0K after
Aug 26, 2024 (view filing)Aug 22-234 daysForsyth DouglasDirectorPPurchase+75.0K$13.83+$1.04M+50.1%224.6K after2 lots
Aug 22, 2024 (view filing)Aug 20-212 daysLappe MarkChief Executive OfficerPPurchase+40.0K$12.96+$518.3K+269.1%54.9K after2 lots
Jun 7, 2024 (view filing)Jun 52 daysKayyem Jon FaizDirectorPPurchase+57.5K$17.32+$997.0K+5.3%1.15M after2 lots
Jun 4, 2024 (view filing)May 31-Jun 44 daysKayyem Jon FaizDirectorPPurchase+286.8K$17.18+$4.93M+35.6%1.09M after5 lots